Article
Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.
Circulation. Heart failure - 1 Dec 2020
Lanfear David E, Luzum Jasmine A, She Ruicong, Gui Hongsheng, Donahue Mark P, O'Connor Christopher M, Adams Kirkwood F, Sanders-van Wijk Sandra, Zeld Nicole, Maeder Micha T, Sabbah Hani N, Kraus William E, Brunner-LaRocca Hans-Peter, Li Jia, Williams L Keoki
Abstract excerpt
BACKGROUND: β-Blockers (BBs) are mainstay therapy for heart failure with reduced ejection fraction. However, individual patient responses to BB vary, which may be partially due to genetic variation. The goal of this study was to derive and validate the first polygenic response predictor (PRP) for BB survival benefit in heart failure with reduced ejection fraction patients. METHODS: Derivation and validation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.